Skip to main content

Web Exclusives

HOPA Corner

Embracing Equity: The Evolving Role of HOPA in Advancing Fairness, Access, and Representation

Immunotherapy

HARMONI-2 Demonstrating “Significant” Improvement in PFS With Ivonescimab Over Pembrolizumab

Lymphoma

Group Aiming to Cure Follicular Lymphoma Awarded $2.25 Million

Perspective

Prescription Drug Provisions in the Inflation Reduction Act of 2022: A Payer Perspective

FDA Updates

FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management

Jerm Day-Storms, PhD, MWC

FDA Updates

Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma

FDA Updates

Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma

FDA Updates

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma

FDA Updates

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma

FDA Updates

Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation

Page 2 of 43
Results 11 - 20 of 430